Punicalagin inhibits inflammation in LPS-induced RAW264.7 macrophages via the suppression of TLR4-mediated MAPKs and NF-κB activation

Inflammation

Volumn 37, Issue 3, 2014, Pages 956-965

  Xu, Xiaolong ^a   Yin, Peng ^a   Wan, Changrong ^a   Chong, Xinlu ^b   Liu, Mingjiang ^a   Cheng, Peng ^b   Chen, Jiajia ^b   Liu, Fenghua ^b   Xu, Jianqin ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF AGRICULTURE   (China)

Author keywords

anti inflammation; MAPKs; NF B; proinflammatory cytokines; punicalagin

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN KINASE; PUNICALAGIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; I KAPPA B; IL1B PROTEIN, MOUSE; MESSENGER RNA; NF-KAPPAB INHIBITOR ALPHA; NOS2 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; RELA PROTEIN, MOUSE; TANNIN; TLR4 PROTEIN, MOUSE; TRANSCRIPTION FACTOR RELA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; IN VITRO STUDY; MACROPHAGE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; CHINESE MEDICINE; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; PHOSPHORYLATION;

LYTHRACEAE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2; DINOPROSTONE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYDROLYZABLE TANNINS; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPOPOLYSACCHARIDES; MACROPHAGES; MEDICINE, CHINESE TRADITIONAL; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902546794     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9816-2     Document Type: Article

References (40)

1. Nathan, C. 2002. Points of control in inflammation. Nature 420: 846-852.
2. Hsu, C.C., J.C. Lien, C.H. Chang, S.C. Kuo, and T.F. Huang. 2013. Yuwen 02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NF-κB and MAPK activation. Biochemical Pharmacology 85: 385-395.
3. Zingarelli, B., M. Sheehan, and H.R. Wong. 2003. Nuclear factor-κB as a therapeutic target in critical care medicine. Critical Care Medicine 31: S105-S111.
4. Heiss, E., C. Herhaus, K. Klimo, H. Bartsch, and C. Gerhauser. 2001. Nuclear factor Kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. Journal of Biological Chemistry 276: 32008-32015.
5. Rim, H.K., W. Cho, S.H. Sung, and K.T. Lee. 2012. Nodakenin suppresses lipopolysaccharide induced inflammatory responses in macrophage cells by inhibiting tumor necrosis factor receptor -associated factor 6 and nuclear factor-κB pathways and protects mice from lethal endotoxin shock. Journal of Pharmacology and Experimental Therapeutics 342: 654-664.
6. Yona, S., and S. Jung. 2010. Monocytes: subsets, origins, fates and functions. Current Opinion in Hematology 17: 53-59.
7. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. International Immunology 17: 1-14.
8. Aderem, A., and R.J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406: 782-787.
9. Ci, X., R. Ren, K. Xu, H. Li, Q. Yu, Y. Song, D. Wang, R. Li, and X. Deng. 2010. Schisantherin A exhibits anti-inflammatory properties by down regulating NF-κB and MAPK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Inflammation 33: 126-136.
10. Cerda, B., R. Llorach, J.J. Ceron, J.C. Espin, and F.A. Tomas-Barberan. 2003. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. European Journal of Nutrition 42: 18-28.
11. Cerda, B., J.J. Ceron, F.A. Tomas-Barberan, and J.C. Espin. 2003. Repeated oral administration of high doses of pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. Journal of Agricultural and Food Chemistry 51: 3493-3501.
12. Adams, L.S., N.P. Seeram, B.B. Aggarwal, Y. Takada, D. Sand, and D. Heber. 2006. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. Journal of Agricultural and Food Chemistry 54: 980-985.
13. Aqil, F., R. Munagala, M.V. Vadhanam, H. Kausar, J. Jeyabalan, D.J. Schultz, and R.C. Gupta. 2012. Anti-proliferative activity and protection against oxidative DNA damage by punicalagin isolated from pomegranate husk. Food Research International 49: 345-353.
14. Zhang, X.H., H. Lei, A.J. Liu, Y.X. Zou, F.M. Shen, and D.F. Su. 2011. Increased oxidative stress is responsible for severer cerebral infarction in stroke-prone spontaneously hypertensive rats. CNS Neuroscience & Therapeutics 17: 590-598.
15. Marin, M., R. Maria Giner, J.L. Rios, and M. Carmen Recio. 2013. Intestinalanti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. Journal of Ethnopharmacology 150: 925-934.
16. Arseculeratne, S.N., A.A. Gunatilaka, and R.G. Panabokke. 1985. Studies on medicinal plants of Sri Lanka: Part 14. Toxicity of some traditional medicinal herbs. Journal of Ethnopharmacology 13: 323-335.
17. Saxena, A., and N.K. Vikram. 2004. Role of selected Indian plants in management of type 2 diabetes: a review. Journal of Alternative and Complementary Medicine 10: 369-378.
18. Aviram, M., L. Dornfield, M. Rosenblatt, N. Volkova, M. Kaplan, R. Coleman, T. Hayek, D. Presser, and B. Fuhrman. 2000. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. American Journal of Clinical Nutrition 71: 1062-1076.
19. Kaplan, M., T. Hayek, A. Raz, R. Coleman, L. Dornfeld, J. Vaya, and M. Aviram. 2001. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. Journal of Nutrition 131: 2082-2089.
20. Gil, M.I., F.A. Tomas-Barberan, B. Hess-Pierce, D.M. Holcroft, and A.A. Kader. 2000. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. Journal of Agricultural and Food Chemistry 48: 4581-4589.
21. Lee, S.I., B.S. Kim, K.S. Kim, S. Lee, K.S. Shin, and J.S. Lim. 2008. Immune-suppressive activity of punicalagin via inhibition of NFAT activation. Biochemical and Biophysical Research Communications 371: 799-803.
22. Jean-Gilles, D., L. Li, V.G. Vaidyanathan, R. King, B. Cho, D.R. Wortnen, C.O. Chichester, and N.P. Seeram. 2013. Inhibitory effects of polyphenol punicalagin on type-II collagen degradation in vitro and inflammation in vivo. Chemico-Biological Interactions 205: 90-99.
23. Laskin, D.L., and K.J. Pendino. 1995. Macrophages and inflammatory mediators in tissue injury. Annual Review of Pharmacology and Toxicology 35: 655-677.
24. Sharma, J.N., O.A. Al, and S.S. Parvathy. 2007. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 15: 252-259.
25. Yayeh, T., M. Hong, Q. Jia, Y.C. Lee, H.J. Kim, E. Hyun, T.W. Kim, and M.H. Rhee. 2012. Pistacia chinensis inhibits NO production and upregulates HO-1 induction via PI-3 K/Akt pathway in LPS stimulated macrophage cells. American Journal of Chinese Medicine 40: 1085-1097.
26. Han, S., J.H. Lee, C. Kim, D. Nam, W.S. Chung, S.G. Lee, K.S. Ahn, S.K. Cho, M. Cho, and K.S. Ahn. 2013. Capillarisin inhibits iNOS, COX-2 expression, and proinflammatory cytokines in LPS-induced RAW 264.7 macrophages via the suppression of ERK, JNK, and NF-κB activation. Immunopharmacology and Immunotoxicology 35: 34-42.
27. Turini, M.E., and R.N. DuBois. 2002. Cyclooxygenase-2: a therapeutic target. Annual Review of Medicine 53: 35-57.
28. Rocca, B., and G.A. FitzGerald. 2002. Cyclooxygenases and prostaglandins: shaping up the immune response. International Immunopharmacology 2: 603-630.
29. Singh, V.P., C.S. Patil, N.K. Jain, and S.K. Kulkarni. 2004. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology 72: 77-84.
30. Kim, S.J., H.J. Jeong, P.D. Moon, H.M. Lee, H.J. Jung, S.K. Jung, H.K. Rhee, D.C. Yang, S.H. Hong, and H.M. Kim. 2005. Anti-inflammatory activity of gumiganghwaltang through the inhibition of nuclear factor-kappa B activation in peritoneal macrophages. Biological & Pharmaceutical Bulletin 28: 233-237.
31. Ling, M., Y. Li, Y. Xu, Y. Pang, L. Shen, R. Jiang, Y. Zhao, X. Yang, J. Zhang, J. Zhou, X. Wang, and Q. Liu. 2012. Regulation of miRNA-21 by reactive oxygen species-activated ERK/NF-κB in arsenite-induced cell transformation. Free Radical Biology and Medicine 52: 1508-1518.
32. Han, D.W., M.H. Lee, H.H. Kim, S.H. Hyon, and J.C. Park. 2011. Epigallocatechin-3-gallate regulates cell growth, cell cycle and phosphorylated nuclear factor-κB in human dermal fibroblasts. Acta Pharmacologica Sinica 32: 637-646.
33. Checker, R., R.S. Patwardhan, D. Sharma, J. Menon, M. Thoh, H.N. Bhilwade, T. Konishi, and S.K. Sandur. 2012. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-κB. Free Radical Biology and Medicine 53: 1421-1430.
34. Dai, J.N., Y. Zong, L.M. Zhong, Y.M. Li, W. Zhang, L.G. Bian, Q.L. Ai, Y.D. Liu, J. Sun, and D. Lu. 2011. Gastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulatedmicroglia via MAPK pathways. PloS One 6: e21891.
35. Liu, H.T., P. Huang, P. Ma, Q.S. Liu, C. Yu, and Y.G. Du. 2011. Chitosan oligosaccharides suppress LPS-induced IL-8 expression in human umbilical vein endothelial cells through blockade of p38 and Akt protein kinases. Acta Pharmacologica Sinica 32: 478-486.
36. Liu, C., X. Zhang, J.X. Zhou, W. Wei, D.H. Liu, P. Ke, G.F. Zhang, G.J. Cai, and D.F. Su. 2013. The protective action of ketanserin against lipopolysaccharide induced shock in mice is mediated by inhibiting inducible NO synthase expression via the MEK/ERK pathway. Free Radical Biology and Medicine 65: 658-666.
37. Choi, Y., M.K. Lee, S.Y. Lim, S.H. Sung, and Y.C. Kim. 2009. Inhibition of inducible NO synthase, cyclooxygenase-2 and interleukin-1beta by torilin is mediated by mitogen-activated protein kinases in microglial BV2 cells. British Journal of Pharmacology 156: 933-940.
38. Kawasaki, K., S. Akashi, R. Shimazu, T. Yoshida, K. Miyake, and M. Nishijima. 2001. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by taxol. Journal of Endotoxin Research 7: 232-236.
39. Baker, R.G., M.S. Hayden, and S. Ghosh. 2011. NF-κB, inflammation, and metabolic disease. Cell Metabolism 13: 11-22.
40. Theoharides, T.C., D. Kempuraj, M. Tagen, P. Conti, and D. Kalogeromitros. 2007. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunological Reviews 217: 65-78.